Clinical trial
Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage…
NCT00003328 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00003328 |
|---|---|
| Title | Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer |
| Official title | A Phase III Double-Blind, Randomised, Placebo-Controlled Study of Porfiromycin When Used as an Adjuvant to Radiation Therapy in Patients With Head and Neck Cancer |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug, Radiation |
| Interventions | porfiromycin, radiation therapy |
| Enrollment | 600 |
| Start date | Dec 1, 1997 |
| First posted | Jul 16, 2004 |
| Last update posted | May 21, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: